Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate Update
February 16, 2022 06:15 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast...
Editas Medicine Reports on Recent Progress and Outlook at J.P. Morgan Healthcare Conference
January 10, 2022 07:00 ET
|
Editas Medicine, Inc.
Anticipated 2022 milestones include initial clinical data for EDIT-301 in sickle cell disease by year-end, dosing of first TDT patient with EDIT-301, initiation of pediatric high-dose cohort for...
Editas Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 04, 2022 06:58 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will present a company overview and update at the...
Editas Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for EDIT-301 for the Treatment of Transfusion-Dependent Beta Thalassemia
December 20, 2021 07:00 ET
|
Editas Medicine, Inc.
EDIT-301 is in development as a transformative, one-time treatment for people living with transfusion-dependent beta thalassemia Editas Medicine will initiate a Phase 1/2 clinical trial in 2022 ...
Editas Medicine Reports Preclinical Data Demonstrating Robust Tumor Reduction and Clearance Using Novel, Engineered iNK Cells at the American Society of Hematology Annual Meeting
December 12, 2021 18:00 ET
|
Editas Medicine, Inc.
Preclinical data demonstrating Editas-engineered AsCas12a multiplexed editing of iPSCs enhances iNK tumor killing ability, supporting promise as a potential therapeutic approach for solid tumors iNKs...
Editas Medicine Presents Preclinical Data on Novel Engineered iPSC-derived NK Cells for the Treatment of Cancer at the Society for Immunotherapy of Cancer 36th Annual Meeting
November 12, 2021 07:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced preclinical data on its progress in the development of...
Editas Medicine Announces Third Quarter 2021 Results and Business Updates
November 08, 2021 07:00 ET
|
Editas Medicine, Inc.
EDIT-101 Phase 1/2 BRILLIANCE trial initial clinical data demonstrated favorable safety profile and preliminary evidence of clinical benefit; enrollment ongoing in adult high-dose and pediatric...
Editas Medicine to Present Data Demonstrating Progress Towards Transformative Gene Editing Medicines for the Treatment of Hemoglobinopathies and Cancer at the ASH Annual Meeting and Exposition
November 04, 2021 09:02 ET
|
Editas Medicine, Inc.
EDIT-301 preclinical data support differentiated approach to develop a transformative medicine for people living with transfusion-dependent beta thalassemia Preclinical data demonstrating proprietary...
Editas Medicine Names Bernadette Connaughton to Board of Directors
October 28, 2021 09:00 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it has appointed Bernadette Connaughton to its...
Editas Medicine to Host Conference Call Discussing Third Quarter 2021 Results and Corporate Update
October 25, 2021 16:01 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast...